Document is current

Any future updates will be listed below

1164 Systemic administration of AXA-042, a novel TLR2/6 agonist, reshapes the tumor microenvironment, as revealed by single cell sequencing analysis

Crossref DOI link: https://doi.org/10.1136/jitc-2022-SITC2022.1164

Published Online: 2022-11-07

Published Print: 2022-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark